Felicetta J V, Green W L, Nelp W B
J Clin Invest. 1980 May;65(5):1032-40. doi: 10.1172/JCI109755.
Subsequent to studies indicating that cholecystographic agents and sulfobromophthalein (BSP) inhibit uptake of thyroxine (T(4)) by rat liver slices, the effect of such compounds on hepatic storage of T(4) in man has been examined. After intravenous administration of [(125)I]T(4) to five normal subjects, hepatic radioactivity, estimated by external gamma counting, rose to a peak in approximately 4 h and then declined in parallel with serum radioactivity. When a 6-g dose of the cholecystographic agent, tyropanoate (Bilopaque), was administered orally 3 d later, estimated hepatic extravascular radioactivity fell 50-60% within 4 h and then rose toward the pretyropanoate value. Concomitant with the fall in hepatic radioactivity, serum radioactivity rose 57-70%, as did stable T(4) levels in serum, suggesting that hormone discharged from the liver entered the serum. Both uptake of T(4) and discharge by tyropanoate were much less in two patients with liver disease. Ipodate (Oragrafin), 12 g orally in two subjects, caused much smaller changes in hepatic and serum radioactivity. However, ipodate also caused a doubling of the percent free T(4) in the serum as judged by equilibrium dialysis, and the ratio of hepatic radioactivity to free [(125)I]T(4) in serum declined markedly after ipodate, similar to the fall in hepatic:serum (125)I ratios after tyropanoate. BSP, 20 mg/kg i.v. in three subjects, caused a smaller change; the decline in hepatic T4 content averaged 19%. We conclude that these organic anions, tyropanoate, ipodate, and BSP, all can displace T(4) from the liver. The results imply a link between T(4) transport and organic anion transport, and indicate a mechanism for altering hepatic T(4) content in man that could be the site of physiologic regulation or of disease. A method is described whereby analysis of the change in hepatic and plasma radioactivity after tyropanoate could be employed to estimate hepatic T(4) content in diverse clinical circumstances.
在有研究表明胆囊造影剂和磺溴酞钠(BSP)会抑制大鼠肝切片摄取甲状腺素(T4)之后,人们对这类化合物对人体肝脏中T4储存的影响进行了研究。给5名正常受试者静脉注射[125I]T4后,通过体外γ计数估算的肝脏放射性在约4小时内升至峰值,然后与血清放射性平行下降。3天后口服6克剂量的胆囊造影剂碘番酸(Bilopaque),估算的肝脏血管外放射性在4小时内下降了50 - 60%,然后又回升至碘番酸给药前的值。随着肝脏放射性的下降,血清放射性上升了57 - 70%,血清中稳定的T4水平也是如此,这表明从肝脏释放的激素进入了血清。在两名肝病患者中,碘番酸对T4的摄取和释放作用要小得多。给两名受试者口服12克碘泊酸盐(Oragrafin),肝脏和血清放射性的变化要小得多。然而,根据平衡透析判断,碘泊酸盐也使血清中游离T4的百分比增加了一倍,并且碘泊酸盐给药后肝脏放射性与血清中游离[125I]T4的比值明显下降,类似于碘番酸给药后肝脏:血清125I比值的下降。给三名受试者静脉注射20毫克/千克的BSP,引起的变化较小;肝脏T4含量平均下降了19%。我们得出结论,这些有机阴离子,即碘番酸、碘泊酸盐和BSP,都能将T4从肝脏中置换出来。这些结果暗示了T4转运与有机阴离子转运之间的联系,并表明了一种改变人体肝脏T4含量的机制,这可能是生理调节或疾病发生的部位。本文描述了一种方法,通过该方法可以利用分析碘番酸给药后肝脏和血浆放射性的变化来估算不同临床情况下的肝脏T4含量。